Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in Alnylam Pharmaceuticals by 7.6%, now owning 26,915 shares valued at approximately $7.27 million.
• Alnylam Pharmaceuticals reported $0.32 earnings per share (EPS) for the last quarter, significantly exceeding analysts' expectations of ($0.54) and showing a 17.3% revenue increase year-over-year.
• Insiders, including CEO Yvonne Greenstreet, have sold a total of 82,385 shares of Alnylam Pharmaceuticals stock valued at approximately $29.27 million over the last three months.

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,915 shares of the biopharmaceutical company's stock after selling 2,200 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Alnylam Pharmaceuticals were worth $7,268,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Whipplewood Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the period. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $28,000. Colonial Trust Co SC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, Washington Trust Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 61 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,979 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the sale, the chief executive officer directly owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. The trade was a 11.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,269,508.61. This represents a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 108,531 shares of company stock worth $41,087,238 over the last three months. Insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent research reports. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Bank of America increased their price target on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Wall Street Zen raised Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Truist Financial assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 price target for the company. Finally, Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $405.33.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $5.3170 during mid-day trading on Wednesday, reaching $463.5970. 368,817 shares of the company were exchanged, compared to its average volume of 953,996. The company has a fifty day simple moving average of $351.27 and a 200-day simple moving average of $292.97. The firm has a market cap of $60.77 billion, a PE ratio of -187.69 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $464.68. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773,689 billion for the quarter, compared to the consensus estimate of $633.54 million. During the same quarter last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.